S0356: A phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma

Journal of Clinical Oncology

Volumn 29, Issue 34, 2011, Pages 4555-4560

  Leichman, Lawrence P ^a   Goldman, Bryan H ^d   Bohanes, Pierre O ^b   Lenz, Heinz J ^b   Thomas, Charles R ^f   Billingsley, Kevin G ^f   Corless, Christopher L ^f   Iqbal, Syma ^a   Gold, Philip J ^e   Benedetti, Jacqueline K ^d   Danenberg, Kathleen D ^c   Blanke, Charles D ^g  

^a Department of Internal Medicine   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Response Genetics   (United States)

^d SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^e SWEDISH MEDICAL CENTER   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; MESSENGER RNA; MOLECULAR MARKER; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DNA REPAIR; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGUS RESECTION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; HYPOKALEMIA; HYPONATREMIA; INFECTION; KIDNEY DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; ORAL MUCOSITIS; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE FRACTIONATION; SKIN TOXICITY; SURGICAL MORTALITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; RADIOTHERAPY, ADJUVANT;

EID: 83355163397     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.7490     Document Type: Article

References (22)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
2. Tepper J, Krasna MJ, Niedzwiecki D, et al: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy and surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26:1086-1092, 2008
3. Gaast AV, van Hagen P, Hulshof M, et al: Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. J Clin Oncol 28:302s, 2010 (suppl 15s; abstr 4004)
4. von Rahden BH, Stein HJ, Siewert JR: Surgical management of esophago-gastric junction tumors. World J Gastroenterol 12:6608-6613, 2006 (Pubitemid 44794936)
5. Suntharalingam M: Radiation therapy for esophageal cancer. Chest Surg Clin N Am 10:569-581, 2000
6. Meguid RA, Hooker CM, Taylor JT, et al: Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: Does the pattern of recurrence differ for patients with complete response and those with partial or no response? J Thorac Cardiovasc Surg 138:1309-1317, 2009
7. Ku GY, Ilson DH: Principles of system therapy, in Job BA, Thomas CR Jr, Hunter JG (eds): Esophageal Cancer: Principles of Practice. New York, NY, Demos Medical Publishing, 2009
8. Vogel U, Dydahl M, Frentz G, et al: DNA repair capacity: Inconsistency between effect of overexpression of five NER gene and the correlation to mRNA levels in the primary lymphocytes. Mutat Res 461:197-210, 2000
9. Metzger R, Leichman CG, Danenberg KD, et al: ERCC1 levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16:309-316, 1998 (Pubitemid 28041614)
10. Cobo M, Isa D, Massuti B, et al: Customizing cisplatin based on quantitative excision repair cross complementing 1 mRNA expression: A phase III trial in non-small cell lung cancer. J Clin Oncol 25:2747-2754, 2007 (Pubitemid 47123183)
11. Shirota Y, Stoehlmacher J, Brabender J, et al: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298-4304, 2001 (Pubitemid 33096777)
12. Lenz HJ, Leichman CG, Leichman L, et al: Molecular markers as indicators of response and outcome in primary gastric cancer. Prog Gastric Cancer Res 2:1295-1300, 1997
13. Khushalani NI, Leichman CG, Proulx G, et al: Oxaliplatin combination with protracted infusion 5-fluorouracil and radiation: Report of a clinical trial for patients with esophageal cancer. J Clin Oncol 20:2844-2850, 2002 (Pubitemid 34651513)
14. Leichman L, Lawrence D, Leichman CG, et al: Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: Characterization and exploratory analysis with survival. J Chemother 18:514-524, 2006
15. Breiman L, Friedman J, Olshen RA: Classification and Regression Trees. Belmont, CA, Wadsworth International Group, 1984
16. Hilsenbeck SG, Clark GM: Practical p-value adjustment for optimally selected cutpoints. Stat Med 15:103-112, 1996 (Pubitemid 26016014)
17. Therneau TM, Atkinson B, Ripley B: The RPART R-Package: Recursive partitioning and regression trees. http://cran.r-project.org/web/packages/rpart/ index.html
18. Urba SG, Orringer MB, Turrisi A, et al: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19:305-313, 2001 (Pubitemid 32112841)
19. Walsh TN, Noonan N, Hollywood D, et al: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335:462-467, 1996 (Pubitemid 26269945)
20. Burmeister BH, Smithers BM, Gebski V, et al: Surgery alone versus chemoradiotherapy followed by surgery for respectable cancer of the oesophagus: A randomized controlled phase III trial. Lancet Oncol 6:659-668, 2005 (Pubitemid 41222756)
21. Stahl M, Walz MK, Stuschke M, et al: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851-856, 2009
22. Joshi MB, Shirota Y, Danenberg KD, et al: High gene expression of TS1, GSTP1 and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 11:2215-2221, 2005